PCSK9 Inhibitors: From Innovation to Sustainable Clinical Application

被引:5
作者
Lekuona, Inaki [1 ]
机构
[1] Hosp Galdakao Usansolo OSI Barrualde, Serv Cardiol, Galdakao, Vizcaya, Spain
来源
REVISTA ESPANOLA DE CARDIOLOGIA | 2018年 / 71卷 / 12期
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; COST-EFFECTIVENESS; TREATMENT GOALS; EVOLOCUMAB; RISK; ADOLESCENTS; ATTAINMENT; EZETIMIBE; OUTCOMES;
D O I
10.1016/j.rec.2018.06.032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:996 / 998
页数:3
相关论文
共 19 条
[1]   Inflammatory and Cholesterol Risk in the FOURIER Trial [J].
Bohula, Erin A. ;
Giugliano, Robert P. ;
Leiter, Lawrence A. ;
Verma, Subodh ;
Park, Jeong-Gun ;
Sever, Peter S. ;
Pineda, Armando Lira ;
Honarpour, Narimon ;
Wang, Huei ;
Murphy, Sabina A. ;
Keech, Anthony ;
Pedersen, Terje R. ;
Sabatine, Marc S. .
CIRCULATION, 2018, 138 (02) :131-140
[2]   Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention [J].
Bohula, Erin A. ;
Morrow, David A. ;
Giugliano, Robert P. ;
Blazing, Michael A. ;
He, Ping ;
Park, Jeong-Gun ;
Murphy, Sabina A. ;
White, Jennifer A. ;
Kesaniemi, Y. Antero ;
Pedersen, Terje R. ;
Brady, Adrian J. ;
Mitchel, Yale ;
Cannon, Christopher P. ;
Braunwald, Eugene .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (08) :911-921
[3]   Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT [J].
Bohula, Erin A. ;
Giugliano, Robert P. ;
Cannon, Christopher P. ;
Zhou, Jing ;
Murphy, Sabina A. ;
White, Jennifer A. ;
Tershakovec, Andrew M. ;
Blazing, Michael A. ;
Braunwald, Eugene .
CIRCULATION, 2015, 132 (13) :1224-1233
[4]   Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) [J].
Bonaca, Marc P. ;
Nault, Patrice ;
Giugliano, Robert P. ;
Keech, Anthony C. ;
Pineda, Armando Lira ;
Kanevsky, Estella ;
Kuder, Julia ;
Murphy, Sabina A. ;
Jukema, J. Wouter ;
Lewis, Basil S. ;
Tokgozoglu, Lale ;
Somaratne, Ransi ;
Sever, Peter S. ;
Pedersen, Terje R. ;
Sabatine, Marc S. .
CIRCULATION, 2018, 137 (04) :338-350
[5]   Treatment of Heterozygous Familial Hypercholesterolemia in Children and Adolescents: An Unsolved Problem [J].
Civeira, Fernando ;
Plana, Nuria .
REVISTA ESPANOLA DE CARDIOLOGIA, 2017, 70 (06) :423-424
[6]  
Lima AOD, 2018, REV ESP CARDIOL, V71, P1027, DOI [10.1016/j.rec.2018.05.003, 10.1016/j.recesp.2018.02.013]
[7]  
Garcia-Gil M Del Mar, 2011, Inform Prim Care, V19, P135
[8]   Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting [J].
Korman, Max ;
Wisloff, Torbjorn .
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2018, 4 (01) :15-22
[9]  
Ministerio de Sanidad Servicios Sociales e Igualdad, 2016, PTEVOLOCUMABV1030320
[10]   Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up [J].
Perez de Isla, Leopoldo ;
Alonso, Rodrigo ;
Watts, Gerald F. ;
Mata, Nelva ;
Saltijeral Cerezo, Adriana ;
Muniz, Ovidio ;
Fuentes, Francisco ;
Luis Diaz-Diaz, Jose ;
de Andres, Raimundo ;
Zambon, Daniel ;
Rubio-Marin, Patricia ;
Barba-Romero, Miguel A. ;
Saenz, Pedro ;
Sanchez Munoz-Torrero, Juan F. ;
Martinez-Faedo, Ceferino ;
Miramontes-Gonzalez, Jose P. ;
Badimon, Lina ;
Mata, Pedro .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (11) :1278-1285